title: [Prognostic analysis of non-cytogenetic factors in elderly adults with acute myeloid leukemia].
abstract: OBJECTIVE
  To analyze the prognostic factors in elderly patients with acute myeloid leukemia (AML).
  
  
  METHODS
  The clinical data of 211 AML patients with age 55 years or over and treated in Shanghai Jiaotong University Medical School affiliated Ruijin Hospital from 2007 to 2011 were collected and analyzed. Multivariate and univariate analysis of clinical data were performed using a Cox regression model and log-rank test, including age, subtype, performance status, white blood cell count, serum LDH and albumin level, and treatment strategy.
  
  
  RESULTS
  Acute promyelocytic leukemia (APL) patients had longer survival than other subtypes. To rule out the impact of APL on the prognostic analysis, we conducted multivariate and univariate analysis excluding APL patients. The significant parameters of the univariate analysis were age (P = 0.003), achieving remission (P < 0.01), performance status (P < 0.01), organ dysfunction (P < 0.01), increased WBC counts (P = 0.022), increased LDH level (P = 0.006) and low albumin level (P < 0.01). Multivariate analysis showed that only failure of achieving remission (P < 0.01), poor performance status (ECOG 3-4) (P < 0.01) and increased WBC counts (P < 0.01) were independent prognostic factors. The patients aged 70 years or over had poor overall survival, and no significant difference of OS was observed among patients with age between 55 and 69 years. For patients aged 55 - 69 years received either DA/IA or CAG treatments had longer survival than those with palliative treatments. For those aged 70 years or over, only patients with CAG treatment had significantly longer survival than palliative treatment. For the patients with age less than 70 years and achieving complete remission after induction, intermediate-dose cytarabine consolidation might not improve survival.
  
  
  CONCLUSIONS
  Elderly AML patients should be treated individually. The intermediate-dose cytarabine consolidation might not improve survival of elderly AML patients.
authors.affiliation: Department of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai, China.
authors.forename: Bing-bing
authors.initials: BB
authors.lastname: Zhao
authors.forename: Zheng
authors.initials: Z
authors.lastname: Zhu
authors.forename: Peng-peng
authors.initials: PP
authors.lastname: Xu
authors.forename: Jun-min
authors.initials: JM
authors.lastname: Li
authors.forename: Zhi-xiang
authors.initials: ZX
authors.lastname: Shen
authors.forename: Wei-li
authors.initials: WL
authors.lastname: Zhao
authors.forename: Li
authors.initials: L
authors.lastname: Wang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D015996:Survival Rate